Table 5. “First-dose” reactions*... | American Society of Hematology

Table 5.

“First-dose” reactions* following subcutaneous administration of alemtuzumab as first-line treatment in 41 patients with B-CLL

Event	NCI Grade I/II, %	NCI Grade III^5-151, %
Fever	68	2^5-152
Rigor	15	2
Rash/urticaria	0	0
Hypotension	0	0
Dyspnea	0	0
Nausea/vomiting	0	0
Diarrhea	0	0
Headache	0	0
Fatigue	5	2^5-152
Local injection site reaction	88	2^5-152

Event	NCI Grade I/II, %	NCI Grade III^5-151, %
Fever	68	2^5-152
Rigor	15	2
Rash/urticaria	0	0
Hypotension	0	0
Dyspnea	0	0
Nausea/vomiting	0	0
Diarrhea	0	0
Headache	0	0
Fatigue	5	2^5-152
Local injection site reaction	88	2^5-152

Most side effects disappeared after 1 to 2 weeks during continued alemtuzumab treatment.

No grade IV reactions occurred.

Three patients were withdrawn from the study after 1 week due to grade III fever, fatigue, and pain at injection site, respectively.